Glucose B. Braun

Glucose B. Braun is an intravenous solution for injection that contains glucose monohydrate as the active ingredient. The product is supplied in a sterile liquid form, with the specific concentration not disclosed in the provided data. It is classified as an excipient/solvent and is used primarily as an intravenous carbohydrate solution. Glucose B. Braun is marketed in the European Union and requires a prescription for clinical use.

Glucose B. Braun is indicated for several clinical situations where rapid carbohydrate delivery or fluid replacement is needed.

- Treatment of hypoglycemia when oral glucose is not feasible - Fluid and electrolyte replacement in patients requiring intravenous therapy - Component of parenteral nutrition regimens to provide caloric support - Maintenance of intraoperative blood glucose levels during surgery - Management of metabolic stress in critically ill patients

When administered intravenously, Glucose B. Braun can produce a range of physiological responses, most of which are related to its carbohydrate content.

Common: - Transient hyperglycemia - Local irritation or phlebitis at the infusion site - Mild electrolyte shifts such as hypernatremia - Nausea or mild gastrointestinal discomfort - Headache - Low-grade fever

Serious: - Severe hyperglycemia requiring medical intervention - Osmotic diuresis leading to dehydration - Anaphylactic or severe allergic reaction - Marked electrolyte disturbances (e.g., hyperkalemia) - Metabolic acidosis in susceptible patients

Safe use of Glucose B. Braun requires attention to patient-specific factors and proper administration techniques.

- Monitor blood glucose levels regularly during infusion - Adjust infusion rate in patients with diabetes or impaired glucose tolerance - Avoid use in patients with uncontrolled severe hyperglycemia - Use caution in individuals with renal or hepatic impairment - Ensure compatibility with other IV solutions before mixing - Observe the catheter site for signs of infection or phlebitis - Consider risk of fluid overload in patients with heart failure

Glucose B. Braun may interact with other intravenous therapies, affecting glucose balance or solution compatibility.

Avoid: - Concurrent high‑dose insulin infusions without close glucose monitoring - Co‑administration with hypertonic saline solutions that may exacerbate electrolyte shifts - Mixing with calcium‑containing solutions that can precipitate - Use with certain potassium supplements without electrolyte monitoring - Simultaneous infusion with incompatible drugs such as some antibiotics

Use with caution: - Concurrent administration of other dextrose‑containing fluids - Use with diuretics that alter electrolyte status - Infusion alongside catecholamines that may raise blood glucose - Co‑administration with glucocorticoids that increase glucose production - Inclusion in total parenteral nutrition admixtures requiring careful calculation